November 04, 2014 | SOURCE: Regen BioPharma, Inc.
FDA issues IND Number for Regen BioPharma’s dCellVax therapeutic application, a proposed treatment for breast cancer
October 28, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma’s Chief Scientific Officer examines potential role of Immunotherapeutic treatment for Ebola in conjunction with other current therapies
October 15, 2014 | SOURCE: Regen BioPharma, Inc.
Cell therapy expert Dr. Amit Patel joins Regen BioPharma Inc. Scientific Advisory Board
October 08, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Inc. files IND application with FDA for dCellVax breast cancer immune therapy
October 06, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma submits experimental protocol to FDA for HemaXellerate Aplastic Anemia trial
October 01, 2014 | SOURCE: BioPharma, Inc.
Regen BioPharma completes preclinical experiments for dCellVax breast cancer immune therapy
September, 16, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma files patent application on new therapy that uses the “Innate” immune system to kill cancer
September, 10, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Provides Update on HemaXellerate IND Progress after conferance call with FDA
August 01, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy
June 11, 2014 10:00 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group Inc. Subsidiary Regen BioPharma Inc. Collaborates on Research Paper Analyzing the Use of Gene Silencing in Heart Transplants